Disease Domain | Count |
---|---|
Neoplasms | 8 |
Nervous System Diseases | 5 |
Endocrinology and Metabolic Disease | 2 |
Infectious Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 18 |
Diagnostic radiopharmaceuticals | 16 |
Contrast agent | 4 |
Chemical drugs | 2 |
Radiopharmaceuticals and diagnostic agent | 1 |
Target |
Mechanism Mcl-1 inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date27 Sep 2024 |
Target |
Mechanism ERs antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 May 2020 |
Target |
Mechanism APP inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 Oct 2013 |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date30 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Indium In-111 Pentetate Disodium | - | Approved |
Iodixanol | Contrast agents More | Approved |
Flutemetamol F-18 ( APP ) | Alzheimer Disease More | Approved |
Regadenoson ( A2aR ) | Coronary angiography More | Approved |
Perflutren protein-type A microspheres(GE healthcare) | Contrast agents More | Approved |